SPRY
ARS Pharmaceuticals, Inc.
$4.11
-0.07
(-1.79%)
Mkt Cap
401.41M
Volume
999,521
52W Range
3.985-13.15
Sector
Healthcare
Beta
0.88
EPS (TTM)
-2.18 USD
P/E Ratio
-6.70
Revenue (TTM)
116.93M USD
Rev Growth (5Y)
+36.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$8.09
Undervalued
strong signal
50.0% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
High-Growth Software
30.0 / 100 pillar composite (overridden)
Fast-growing software, still scaling up — graded A–F vs. similar companies.
Company Description
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.28M | 89.15M | 30,000 | 1.32M | 5.51M | 17.84M | 0 | 0 |
| Net Income | (171.30M) | 8.00M | (54.37M) | (34.68M) | (20.24M) | (1.06M) | (23.97M) | (17.58M) |
| EPS | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -0.03 | -0.72 | -0.53 |
| Free Cash Flow | (171.21M) | 12.98M | (59.44M) | (40.28M) | (17.62M) | 8.15M | (18.99M) | (17.32M) |
| FCF / Share | -1.74 | 0.13 | -0.62 | -1.01 | -0.61 | 0.23 | -0.57 | -0.52 |
| Operating CF | (170.87M) | 13.55M | (59.27M) | (40.08M) | (17.56M) | 9.07M | (18.90M) | (16.88M) |
| Total Assets | 327.65M | 351.15M | 233.19M | 281.44M | 61.45M | 26.41M | 15.65M | 27.55M |
| Total Debt | 96.37M | 42,000 | 274,000 | 481,000 | 9.03M | 10.02M | 15.62M | 7.73M |
| Cash & Equiv | 41.32M | 50.82M | 70.97M | 210.52M | 60.06M | 24.52M | 9.98M | 20.16M |
| Book Value | 114.26M | 256.80M | 230.76M | 272.89M | (31.27M) | (14.05M) | (5.60M) | 18.20M |
| Return on Equity | -1.50 | 0.03 | -0.24 | -0.13 | N/A | N/A | N/A | -0.97 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.66M | 22.68M | 28.09M | 32.50M | 15.72M | 7.97M | 86.58M | 2.07M | 500,000 | 0 | 0 | 0 |
| Net Income | (62.34M) | (60.62M) | (41.32M) | (51.15M) | (44.88M) | (33.94M) | 49.93M | (19.13M) | (12.52M) | (10.29M) | (7.17M) | (14.87M) |
| EPS | -0.63 | -0.61 | -0.42 | -0.52 | -0.46 | -0.35 | 0.51 | -0.20 | -0.13 | -0.11 | -0.07 | -0.16 |
| Free Cash Flow | (60.93M) | (44.95M) | (43.48M) | (47.24M) | (39.64M) | (40.83M) | 41.70M | (14.61M) | (7.32M) | (6.79M) | (17.31M) | (12.81M) |
| FCF / Share | -0.61 | -0.45 | -0.44 | -0.48 | -0.40 | -0.42 | 0.43 | -0.15 | -0.08 | -0.07 | -0.18 | -0.13 |
| Operating CF | (60.93M) | (44.95M) | (43.48M) | (47.05M) | (39.59M) | (40.74M) | 42.00M | (14.47M) | (7.28M) | (6.71M) | (17.41M) | (12.76M) |
| Total Assets | 249.50M | 287.57M | 327.65M | 372.80M | 313.47M | 327.32M | 351.15M | 217.60M | 221.97M | 227.58M | 233.19M | 248.56M |
| Total Debt | 171.60M | 96.52M | 96.37M | 1.53M | 1.66M | 73,000 | 42,000 | 102,000 | 160,000 | 217,000 | 274,000 | 327,000 |
| Cash & Equiv | 8.16M | 24.32M | 41.32M | 59.56M | 51.54M | 39.86M | 50.82M | 39.66M | 36.63M | 56.01M | 70.97M | 60.53M |
| Book Value | 12.51M | 61.31M | 114.26M | 147.66M | 192.32M | 228.97M | 256.80M | 200.98M | 215.24M | 223.87M | 230.76M | 237.28M |
| Return on Equity | -4.98 | -0.99 | -0.36 | -0.35 | -0.23 | -0.15 | 0.19 | -0.10 | -0.06 | -0.05 | -0.03 | -0.06 |
SPRY News
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY
SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026